Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Acceleron, Additionally, ago, alpha, Alzheimer, American, Amgen, backlog, binding, Biocon, bispecific, Century, cetuximab, China, conjugate, converting, decided, deficient, DFA, diligent, directly, dMMR, Eisai, eleven, endometrial, ESA, fluorouracil, folate, Francisco, fulfilled, HCM, hemoglobin, Hikma, histology, infusion, IO, joint, KCCQ, lack, Leiden, malignant, mCRC, mesothelioma, microtubule, minimum, mismatch, Molina, momentum, Mutual, network, neuroscience, NIH, OSS, ovarian, pleural, preclinical, Prothena, QUAZAR, Questionnaire, receipt, repair, Russia, salvage, SCCHN, shipment, specialty, strength, successor, Sweden, tentative, TIGIT, Torrent, trend, trustee, withdrew
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10 Extension Notice for Revolving Credit Facility Dated September 29, 2011
- 10 Amendment and Waiver to Revolving Credit Facility Dated September 29, 2011
- 10 Extension Notice for Revolving Credit Facility Agreement Dated July 30, 2012
- 10 Amendment to Revolving Credit Facility Dated July 30, 2012
- 31 Exhibit 31.A
- 31 Exhibit 31.B
- 32 Exhibit 32.A
- 32 Exhibit 32.B
- Download Excel data file
- View Excel data file
Related press release
Associated BMY transcripts
BMY similar filings
Filing view
External links
EXHIBIT 32b
Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 (the "Report"), as filed with the Securities and Exchange Commission on July 28, 2021, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bristol-Myers Squibb Company.
/s/ David V. Elkins | ||
David V. Elkins Chief Financial Officer |
July 28, 2021
This written statement is being furnished to the Securities and Exchange Commission as an exhibit to the Report. A signed original of this written statement required by Section 906 has been provided to Bristol-Myers Squibb Company and will be retained by Bristol-Myers Squibb Company and furnished to the Securities and Exchange Commission or its staff upon request.